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which other important clinical
research, such as clinical drug
studies, may be constructed.Methods of Registries
Deﬁnitions. The Agency for
Healthcare Research and Quality
in the United States deﬁnes
a patient registry as “an organized
system that uses observational
study methods to collect uniform
data (clinical and other) to eval-
uate speciﬁed outcomes for a
population deﬁned by a particular
disease, condition, or exposure,and that serves one or more predetermined scientiﬁc, clinical,
or policy purposes” (1). The European Medicines Agency
deﬁnes a registry as “a list of patients presenting with the same
characteristic(s). This characteristic may be a disease or an
outcome (disease registry) or a speciﬁc exposure (exposure or
drug registry)” (2).
The European Medicines Agency deﬁnes cohort studies
as involving “a population-at-risk for an event of interest
followed over time for the occurrence of that event” while
allowing that a registry may, itself, represent a cohort (2).
The Agency for Healthcare Research and Quality deﬁnes
cohort studies as a speciﬁc category of registry distinct from
case-control studies. The term cohort may also be used to
deﬁne a subpopulation of interest within a registry. For
instance, if a registry enrolls both incident and prevalent
patients, analyses may be conducted on one or both of these
cohorts depending on the objective.
The term prevalent may be applied to patients who have
previously received a diagnosis and who may enter a study
when returning for follow-up visits or follow-up treatments.
The term incident is generally used to indicate patients who
have just received a diagnosis as opposed to those patients
who have just experienced onset of symptoms. These
patients are considered incident on the day of diagnosis and
prevalent the day after.
None of the guidelines propose limiting inclusion criteria
in registries to incident patients, although neither of them
explicitly suggest that such a restriction would be ill-advised.
The guidelines do address 3 important issues that should
lead to a study-speciﬁc decision about inclusion/exclusion
criteria: 1) generalizability and carefully deﬁned target
populations; 2) the need for clear objectives to deﬁne theSmithKline, Merck, Novartis, and Pﬁzer. Dr.
d a member of the advisory board of Actelion,
rtis, Pﬁzer, and United Therapeutics as well as
g these companies. All other authors have re-
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013; accepted October 22, 2013.structure and process of data collection; and 3) as noted
in the GRACE (Good Research for Comparative Effec-
tiveness) principles (3), identiﬁcation of the most likely
sources of bias.
Survival, bias, and missing data. Survival is one of the
most common outcomes in registries. The survival curve’s
time frame must be clear. Survival from time of enrollment
in a prevalent cohort can lead to biased results if generalized
to newly diagnosed patients. Conversely, survival from
diagnosis can lead to biased estimates if those results are
generalized to a cohort of prevalent patients at a typical
clinic. Additionally, survival estimates from one incident
cohort may not be generalizable to another incident cohort if
diagnosis methods or time from symptom onset to diagnosis
differ between cohorts.
It is never appropriate to deﬁne an at-risk period that
includes the time during which patients were not in the
study. Doing so leads to immortal time bias (4) because
patients are guaranteed to have survived the pre-study
period. An important difference between immortal time
bias and survivor bias is that there does not exist any
appropriate population to whom analyses with immortal
time bias may be correctly generalized. On the other hand,
survivor bias, a form of selection bias, does not prevent
accurate generalization so long as the results are not incau-
tiously generalized to incident patients.
Due to the lack of randomization, confounding, rather
than selection bias, is often the Achilles heel of registries,
whereas generalizability to a broad cohort is often one of the
greatest strengths. As a result, the guidelines do not suggest
speciﬁc rules for inclusion/exclusion criteria, instead sug-
gesting that the target population, the study objectives, and
avoidance of bias should guide study design decisions.
Missing data are a common methodological problem in
registries because speciﬁc clinical tests are generally not
mandated. Casewise deletion of patients with missing data
can lead to selection bias. If most patients in real practice do
not have complete batteries of testing at regular intervals, the
results of analyses using casewise deletion cannot be gener-
alized to them. Alternative approaches include multiple
imputation (5) or treating missingness as a distinct category.
When outcomes data, rather than risk factor data, are
missing, casewise deletion could lead to even greater biases,
but imputation of outcomes is generally not desirable.
Patients who are lost to follow-up should be censored at the
point in time that they are lost. Care should be taken to
deﬁne the time of last follow-up to ensure that it includes
the time period in which an event would have been reported
and excludes the time period in which an event would not
have been reported.
Current pulmonary arterial hypertension registries. Pul-
monary arterial hypertension (PAH) (group 1 PH) registries
have used different inclusion and exclusion criteria with
respect to the enrollment of newly and previously diagnosed
patients. Lee et al. (6) argue in favor of restricting survival
analyses to incident patients, as in the United Kingdom and
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stratiﬁcation or a delayed entry model accounting for left
truncation is preferable to excluding prevalent patients from
PAH registries. A population is said to be left truncated if
patients may have been excluded from a cohort due to events
that occurred before the study. Patients who die before study
initiation are excluded, whereas patients who survive to study
initiation are included from the point in their survival at
which they were enrolled. An approach to analyzing survival
from diagnosis, using both newly diagnosed and previously
diagnosed patients, was used in the U.S. REVEAL (Registry
to Evaluate Early and Long-Term PAH Disease Manage-
ment) protocol, as well as in the French Registry (8–10).
Survival from time of diagnosis, using data from both
incident and prevalent patients, was estimated both by
Humbert et al. (9) and Benza et al. (10) and are comparable
to survival estimates that are restricted to incident patients
(11). Of note, inclusion of patients with nonconforming
high wedge pressures (pulmonary artery pulmonary wedge
pressure ranging from 16 to 18 mm Hg) has been contro-
versial; however, these patients may be excluded or included
in individual analyses and differences may be evaluated (12).
Analysis: what can be done with the data and what is not
possible? Although literature on design and conduct of
registries is not as extensive as the literature on clinical trials,
observational researchers must begin by reviewing recent
guidelines (3,13,14). Registry data are useful for describing
practice patterns, characterizing populations, assessing
burden of illness, and developing risk stratiﬁcation tools.
The use of registry data for comparative effectiveness is
probably the most controversial study aim (15,16). Because
aggressive treatments will generally be reserved for the
sickest patients, the worst outcomes will occur frequently
among these patients, thereby confounding assessment of
efﬁcacy. A variety of methods exist to adjust for confound-
ing. Matching, multivariable risk-adjusted models of
outcomes and propensity scores can be effective if all con-
founding variables have been identiﬁed and measured. In
PAH, it is plausible that most, but not all, important
potential confounders have been successfully identiﬁed due
to the extensive research that has been published in the past
decade on risk factors. Nonetheless, it is unlikely that all
important confounders have been measured at the time of
treatment selection. Variable time lags between treatment
decision and treatment initiation can also increase the
potential for immortal time bias to enter into a comparative
effectiveness analysis.
Funding. A number of factors can make observational
studies less expensive than randomized trials. Patients can
generally be recruited faster due to broad inclusion criteria
and few barriers to participation. There are usually no
mandated treatments or tests. A risk-based site monitoring
approach reduces the need for full source document veriﬁ-
cation. Some aspects of registries can also make them
more expensive. These include long-term follow-up and
analysis requirements associated with having multiple studyobjectives. Major costs include funding for site coordinators,
project management, in-person meetings, data management,
and statistical analysis. When studies receive industry
sponsorship, the relationship of the sponsor and advisors
must be clearly delineated, and it is similarly important for
data ownership and data access rules to be speciﬁed
contractually. Disclosing conﬂict of interest is critical, but
there are many important scientiﬁc objectives with which the
interests of industry, patients, and the scientiﬁc community
are fully aligned.Characteristics of Major Registries
Baseline. The characteristics of 11 major registries are
shown in Table 1 (17–39). Six countries are represented. All
registries enrolled patients with idiopathic and heritable
PAH, 7 included PAH, and 1 also included chronic
thromboembolic pulmonary hypertension (CTEPH) (PH
Group 4). The number of patients in each registry ranged
from 72 to 3,515, and the number of participating centers
ranged from 1 to 55. Table 2 provides the basic presenting
characteristics of patients enrolled in each registry.
Outcome. Table 3 shows survival over the duration of
reported follow-up. In general, survival improved as treat-
ment options increased. Data from the U.S. REVEAL
suggests that current median survival is 7 years for patients
with PAH (10) compared with 2.8 years for patients with
primary pulmonary hypertension (PPH, now referred to as
idiopathic/heritable PAH) in the U.S. National Institutes of
Health (NIH) Registry (17).The Changing Phenotype of PAH
in the Modern Management Era
Registries have provided important information about
the epidemiology and phenotype of patients with PAH.
Of note, considerable changes in the PAH phenotype
have been observed over the past decades. These include
substantial changes in age, sex, comorbidities, and survival
(Tables 2 and 4) (6,9,19,27,34,37,40). Although the mean
age of patients with idiopathic PAH in the ﬁrst registry
created in 1981 (U.S. NIH Registry) was 36  15 years (18),
PAH is now more frequently diagnosed in elderly patients,
resulting in a mean age at diagnosis between 50  14 and 65
 15 years in current registries (Table 2). Furthermore, the
female predominance is quite variable among registries and
may not be present in elderly patients (39), and survival
appears to have improved over time (Table 3). To know
whether these differences reﬂect a change in the disease
itself, one must determine all of the biases that affect PH
registries and how they differ between registries before any
conclusion can be made that the phenotype of PAH is
actually changing (41). When looking at any registry,
differences need to be identiﬁed between the target pop-
ulation, the accessible population, the intended population,
and the population actually studied. How representative the
Table 1 General Information of PAH Registries From Different Countries and Time Periods
Registry (Ref. #) Study Cohort
Study Design
and Time Period No. of Centers No. of Patients Incidence/Prevalence
Predominant Etiologies
of PAH
U.S. NIH (17,18) IPAH Prospective, 1981–1985 32 187 NA NA
U.S. PHC (19) Group 1 PH, age >18 yrs Retrospective, 1982–2004;
prospective, 2004–2006
3 578 NA IPAH, 48%; CTD-PAH, 30%;
CHD-PAH, 11%
Scottish-SMR (20) Group 1 PH (IPAH, CHD-PAH,
and CTD-PAH), age 16–65 yrs
Retrospective, 1986–2001 NA 374 PAH, 7.6/26 cases/MAI;
IPAH, 2.6/9 cases/MAI
IPAH, 47%; CTD-PAH, 30%;
CHD-PAH, 23%
French (9,21,22) Group 1 PH, age >18 yrs Prospective, 2002–2003 17 674 PAH, 2.4/15 cases/MAI;
IPAH, 1.0/5.9 cases/MAI
IPAH, 39%; CTD-PAH, 15% (SSc, 76%);
CHD-PAH, 11%
Chinese (23) IPAH and HPAH Prospective, 1999–2004 1 72 NA NA
U.S. REVEAL (8,24–33) Group 1 PH Prospective, 2006–2009 55 3,515 (age >3 months) PAH, 2.0/10.6 cases/MAI
IPAH, 0.9 cases/MAI
IPAH, 46%; CTD-PAH, 25% (SSc, 62%);
CHD-PAH, 10%
Spanish (34) Group 1 PH and CTEPH,
age >14 yrs
Retrospective, 1998–2006;
prospective, 2007–2008
31 PAH, 866; CTEPH, 162 PAH, 3.2/16 cases/MAI;
IPAH, 1.2/4.6 cases/MAI
IPAH, 30%; CTD-PAH, 15% (SSc 61%);
CHD-PAH, 16%
UK (6,35) IPAH, HPAH, and anorexigen-
associated PAH
Prospective, 2001–2009 8 482 1.1/6.6 cases/MI NA
New Chinese Registry (36,37) Group 1 PH, age >18 yrs Prospective, 2008–2011 9 956 NA CHD-PAH, 43%; IPAH, 35%;
CTD-PAH, 19% (SLE, 51%; SSc, 9%)
Mayo (38) Group 1 PH Prospective, 1995–2004 1 484 NA IPAH, HPAH 56%; CTD-PAH, 24%,
other, 20%
Compera (39) IPAH, age >18 yrs Prospective, 2007–2011 28 587 NA IPAH, 100%
CHD ¼ congenital heart disease; CTD ¼ connective tissue disease; CTEPH ¼ chronic thromboembolic pulmonary hypertension; HPAH ¼ heritable pulmonary arterial hypertension; IPAH ¼ idiopathic pulmonary arterial hypertension; MAI ¼million adult inhabitants; MI ¼million
inhabitants; NA ¼ not available; NIH ¼ National Institutes of Health; PAH ¼ pulmonary arterial hypertension; PHC ¼ pulmonary hypertension connection; SMR ¼ Scottish morbidity record; SSc ¼ systemic sclerosis.
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D55actual population is of the target population will determine
how generalizable the registry is.
A potential explanation for the change of phenotype may
be the increased awareness for PAH in the modern
management era, as effective therapies are now available.
Because PPH was considered a rare disease that affected
young women at the time of the initial U.S.-NIH registry, it
is likely that older patients and men were often not
considered for the diagnosis at that time. Other factors
contributing to biased enrollment include lack of awareness
of this registry among nonexperts in the community and
unavailability of widespread screening tools such as Doppler
echocardiography. Nowadays, PAH may indeed be detected
more frequently in elderly patients, as the population of most
Western countries is aging. However, one should also be
cautious about possible misclassiﬁcations between PAH and
non-PAH PH (particularly post-capillary PH due to heart
failure with preserved ejection fraction [HFpEF]), which
may occur, particularly in elderly patients as a consequence
of uncertainties in the current deﬁnitions and difﬁculties in
the measurement of the pulmonary arterial wedge pressure.
Registries from China and other developing countries
demonstrate demographics and characteristics similar to the
early studies of the U.S. NIH Registry (23), suggesting that
some differences in phenotype are related to the healthcare
environment rather than to different expressions of the
disease. Nonetheless, speciﬁc sources of systematic bias in
PAH registries include the following: 1) changes in the
classiﬁcation of PH that have led to the inclusion of
a varying spectrum of patients in modern registries; 2)
changing interest in PH by academic physicians producing
more development and dissemination of information; 3)
increased awareness of PH by clinicians due to availability
and marketing of effective therapy, with associated education
from pharmaceutical representatives (42); 4) easier access to
medical information by patients who may then inﬂuence
their referral to specialized care; and 5) widespread use of
noninvasive techniques (Doppler echocardiography), which
allow for disease detection even in the absence of previous
suspicion, thereby leading to a perception of increased
disease prevalence (43). Thus, it appears that the changing
phenotype of patients with PH in modern registries is
potentially inﬂuenced by factors that are independent of the
disease itself.
Prediction and Prognosis Based on
Relevant Registry Data
The U.S. NIH Registry was the ﬁrst to develop a prognostic
equation. Use of this equation in the current treatment era
has limitations; it provides information only on the natural
history of untreated PPH rather than on group 1 PH
(PAH). More recent registries (Tables 1 to 3) have identiﬁed
predictors of outcome (Table 4), which show surprising
homology between studies, including disease etiology, patient
sex, and factors reﬂective of right heart function.
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D56Prognostic equations and calculators. In 4 of the regis-
tries (U.S. REVEAL, U.S. Pulmonary Hypertension
Connection Registry, French registry, and U.K. registry),
multivariable analyses led to the development of prognostic
equations (U.S. REVEAL, U.S. Pulmonary Hypertension
Connection Registry, French registry) (Table 5) or calcula-
tors (U.S. REVEAL, U.K. registry). Despite the U.S.
REVEAL equation’s derivation in a combined incident and
prevalent cohort at the time of enrollment, the equation
demonstrated equal prognostic power when tested at the
time of diagnosis and was validated in an entirely incident
population (40) and in distinct PH populations at other
institutions (38,44,45). The U.K. prognostic score was
validated in a second set of incident patients taken retro-
spectively from the U.K. registry only (derivation was from
the Scottish registry only). The French registry and U.S.
REVEAL equations have shown adequate predictive power
when tested in matched patients from the U.S. REVEAL
and French registries, respectively (46,47). However, the
French registry equation had lower calibration than the U.S.
REVEAL equation when tested in respective matched
populations from each registry. The U.S. REVEAL equa-
tion was also noted to have good calibration in both the U.K.
and Spanish registries, whereas the French registry equation
appears to slightly overestimate the risk of death in these
respective registries. One explanation for this is that the
French registry equation, as opposed to the U.S. REVEAL
equation, was calculated in a cohort of patients recruited in
the 2002/2003 period that partially preceded widespread
and early use of oral therapies for PAH. It is also apparent
that the earlier discussions and concerns about the relative
contribution to mortality risk of newly and previously
diagnosed patients is minimized and overshadowed by the
overall contribution of individual risk proﬁles in each of
these populations, respectively. In other words, a newly
diagnosed patient is not “independently” at risk of dying by
the mere fact of newly receiving a diagnosis, but rather
because they have a larger proportion of at-risk factors than
those who previously received a diagnosis (7,21).Future Directions
Broadening to other PH groups and novel entry criteria.
Although patients belonging to group 2 (PH due to left
heart diseases) and group 3 (PH due to chronic lung
diseases and/or hypoxia) of the PH classiﬁcation represent
an increasing part of the clinical practice, there is dispro-
portionately little information about the demographic
factors and clinical course of this segment of the PH pop-
ulation. This suggests that registry database methodology
may be useful for these groups. The structure of potential
registries incorporating “non-PAH” PH is problematic.
A single registry could include all patients with any type
of PH from which deﬁned subgroups (i.e., PH associated
with interstitial lung disease, chronic obstructive pulmonary
disease, left ventricular systolic dysfunction, or left
Table 4 Multivariate Predictors of Survival
Category Increase Risk Decrease Risk
Demographics Sex (male) and age interaction (>65 yrs)
(9,27,33,40)
Age (6,19)
Male (6,9,27,34)
Etiology: CTD, (6,19,27,34,37,40)
PoPH, (6,34,40); HPAH, (27,40); PVOD (6,34)
Functional capacity Higher NYHA/WHO class (23,40,19,27,34,37)
Lower 6MWD (6,9,27,40)
Lower NYHA/WHO class (19,27)
Higher 6MWD (6,9,27)
Laboratory and biomarkers Higher BNP or NT-proBNP (27,40)
Higher creatinine (27,40)
Lower BNP or NT-proBNP (27)
Imaging Echo: pericardial effusion (27,37,40)
Lung function studies Lower predicted DLCO (27,37,40) Higher predicted DLCO (27,40)
Hemodynamics Higher mRAP (6,19,27,34,40)
Lower CO or CI (6,9,34)
Higher PVR or PVRI (27,40)
Higher CO or CI (19)
BNP ¼ B-type natriuretic peptide; CI ¼ cardiac index; CO ¼ cardiac output; DLCO ¼ diffusing capacity of the lung for carbon monoxide;
Echo ¼ echocardiography; HPAH ¼ heritable pulmonary arterial hypertension; mRAP ¼mean right atrial pressure; NT-proBNP ¼ N-terminal pro–
B-type natriuretic peptide; NYHA ¼ New York Heart Association; PoPH ¼ portopulmonary hypertension; PVOD ¼ portopulmonary hypertension;
PVR ¼ pulmonary vascular resistance; PVRI ¼ pulmonary vascular resistance index; other abbreviations as in Tables 1 and 2.
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D57ventricular HFpEF) could be extracted for analyses. An
advantage of this model is that all patients would be enrolled
from the same sites and would permit direct comparisons
between cohorts with minimal adjustment for differences in
enrollment patterns, location, and follow-up. Disadvan-
tages are that many patients would need to be enrolled to
provide sufﬁcient cohort size for characterization of all
groups, and a single case report form (CRF) may not be
appropriate for all cohorts. The ASPIRE (Assessing the
Spectrum of Pulmonary Hypertension Identiﬁed at
a Referral Centre Registry) has attempted to assess the
spectrum of PH across the 5 PH groups encountered in
a single specialist referral center, allowing speciﬁc descrip-
tions of PH patients with associated diseases such as chronic
obstructive pulmonary disease and other comorbidities
(48,49). However, this approach describes only the
subgroup of patients seen at a referral center and may differ
from the characteristics of patients in the community. An
alternative model would be to develop separate registries
around speciﬁc disease entities of interest, using focusedTable 5 Prognostic Equations for Probability of Survival in PAH
Registry (Ref. #) Equation C Index
U.S. NIH* (17) P(t) ¼ H(t)A(x,y,z) 0.588
Frenchy (21) P(t;x,y,z) ¼ H(t)A(x,y,z) 0.57
PHCz (19) P(t) ¼ e  A(x,y,z)t Not calculated
REVEALx (27) P(1-year) ¼ S0(1)exp(Z0bg) 0.772
*H(t) ¼ 0.88 – 0.14t þ 0.01t2; A(x,y,z) ¼ e(0.007325x þ 0.0526y  0.3275z), where x ¼mean pulmonary
artery pressure; y ¼ mean right-sided atrial pressure; and z ¼ cardiac index. yH(t) ¼ baseline
survival ¼ e(a þ b$t), where a and b are parameters estimated from the multivariate Cox
proportional hazards model, and t is the time from diagnosis measured in years; A(x,y,z) ¼ where x
is the distance walked (m) at diagnosis, y ¼ 1 if female, y ¼ 0 if male, and z is the cardiac output
(l/min) at diagnosis; A(x,y,z) ¼ e((c $ x þ d $ y þ e $ z)), where c and d were parameters obtained from
the Cox proportional hazards model. zP(t) is the probability of survival, t is the time interval in years,
A(x,y,z) ¼ e(1.270  0.0148x þ 0.0402y  0.361z), x ¼ mean pulmonary artery pressure,
y ¼ mean right atrial pressure, z ¼ cardiac index. xS0(1) is the baseline survivor function (0.9698),
Z0b is the linear component, and g is the shrinkage coefﬁcient (0.939).
C index ¼ concordance index; REVEAL ¼ Registry to Evaluate Early and Long-Term PAH Disease
Management; other abbreviations as in Table 1.CRFs at a less anticipated cost. This has been successfully
proposed for CTEPH (50).
Regardless of the disease area of interest, one question
that should be addressed during registry design is whether
the purpose is to obtain information about a precisely
deﬁned disease (option 1) or to examine a more ambigu-
ously delineated study population to determine what
deﬁnes a cohesively deﬁned disease entity in terms of
presentation and natural history (option 2). Option 1 is
most appropriate for diseases in which the criteria for
disease are deﬁnitive, whereas option 2 may be appropriate
for circumstances in which the deﬁnition of the dise-
ase depends on multiple continuous parameters. PH ﬁts
within the second category; 1 registry (U.S. REVEAL) was
constructed to examine whether there is true inhomoge-
neity of presentation and course between patients meeting
classic deﬁnitions of disease versus those outside the deﬁ-
nition (12). This approach has the potential for providing
insight into what the clinically meaningful delimiters of
the disease are.
At-risk population cohorts. Unless all patients who have
PH within a population are enrolled in a registry, estimates
of incidence or prevalence of disease in a pre-speciﬁed
population are not possible. To understand the chances of
PH developing in a population requires that the population
at risk be observed systematically over time to detect the
occurrence of PH. Examples of populations of interest in
whom the risk of the development of PH makes systematic
data collection likely to yield clinically useful information
include patients with known BMPR2 mutations, with 2
family members with PH, with systemic sclerosis, with
cirrhosis and portal hypertension, with past or present
methamphetamine use, with mean pulmonary artery pres-
sure of 20 to 25 mm Hg, or with PH observed only during
exercise.
Because not all factors that may be determinants of
outcome can be anticipated, registries must be designed to
McGoon et al. JACC Vol. 62, No. 25, Suppl D, 2013
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D58accommodate and explore future advances in knowledge as
they develop. This will require that CRFs be ﬂuid enough to
allow changes in coding variables over time, but more
importantly mandates that blood and tissue of participants
be collected and stored so that biomarker and genetic
correlates to clinical phenotypic expression can be examined
both in the present and in the future.
Globalization of registries/collaboration. The proﬁle of
PH varies throughout the world, and comparison between
environments, population demographics, and healthcare
delivery systems may permit the development of hypotheses
about how PH is best diagnosed and managed under
different conditions. Accordingly, systematic acquisition of
clinical data in registries worldwide represents a desirable
objective (51). This would permit insights into a broader
range of PH types to identify commonalities and differences
and would increase the numbers (and therefore strengthen
resulting observations) of patients with any particular
subclassiﬁcation of PH.
Collaborative efforts among registries have been useful in
creating hypotheses about these observations but have been
hampered to an extent by differences in study design, patient
ascertainment, entry criteria, and follow-up. More uniformly
designed and orchestrated registry data acquisition and analysis
will likely yield more coherent observations and conclusions.
The overriding question is not so much whether a global
approach to PH registry data is desirable, but how it could
be achieved. Several models can be considered: 1) a single
global registry with a uniﬁed funding source under the
direction of a single steering committee; 2) a variety of
national or regional registries each with distinct funding
sources and separate steering committees, but using
a common (or overlapping) CRF and comparable enroll-
ment principles; or 3) independently developed and operated
databases using separate CRFs that can be compared using
adjustments for differences to the extent possible during post
hoc collaborations. Of these, model 2 seems to be the best
compromise between collaboration and feasibility.
Registries have been extremely helpful in improving our
understanding of PH. Important questions remain unan-
swered, and it is clear that more registry data will be needed
to address novel questions emerging with improved knowl-
edge of PH. Since the pioneer U.S. NIH Registry of PPH,
recent information gathered from national and international
registries has truly captured many changes in PAH/PH
phenotypes and outcomes in the modern management era.
Besides the registries discussed extensively in the present
paper, others have exclusively studied speciﬁc PH subpop-
ulations discussed in other sections of these proceedings,
with more focus on CTEPH (50), pediatric PH (52–54),
and PAH drug (55) registries.
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